---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211921"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:50:31.526900+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enliven reports Q1 net loss of $23.6M; cash $452.4M; ELVN-001 Phase 1 data mid-2026

## Summary
- Net loss of $23.6M in Q1 2026 vs. $28.5M in Q1 2025; R&D spend $20.7M.
- Cash, cash equivalents and marketable securities of $452.4M as of March 31, 2026; runway into first half of 2029.
- Phase 1 data update for ELVN-001 expected mid-2026; Phase 3 ENABLE-2 initiation expected H2 2026.
- ELVN-001 is a potentially best-in-class ATP-competitive BCR::ABL inhibitor for CML.

## SEC filing metadata
- accession: 0001193125-26-211921
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312526211921/0001193125-26-211921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526211921/elvn-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211921
- JSON: https://secwatch.observer/filing/0001193125-26-211921.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211921.txt

## Source-grounded claims
- claim_id: 9cb0a64c12dd260e7196e7113e77d9bba6d92224
  claim: Enliven Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $23.6 million.
  evidence_excerpt: Enliven reported a net loss of $23.6 million for the first quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312526211921/0001193125-26-211921-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.